Your AI-Trained Oncology Knowledge Connection!
Looking at a subgroup analysis of patients with hormone receptor-positive and HER2-negative breast cancer on endocrine therapy, researchers saw promising results but worrying disparities between non-Hispanic White patients and non-Hispanic Black patients.
Charles Geyer, MD, discusses the potential impact of adjuvant olaparib on the treatment landscape for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.
Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.
The panel discusses challenges that clinicians may experience when ordering biomarker testing for patients with mNSCLC, including insurance coverage barriers, timing of testing, insufficient biopsy samples, and inconclusive test results.
Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.
Panelists discuss available biomarker testing methodologies for metastatic NSCLC (mNSCLC), sharing how they optimize molecular profiling in their practices and whether they typically use commercial or in-house tests.
Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.
Neeta Somaiah, MD, discusses new and upcoming targeted therapies for sarcomas at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.
Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.
Jason Luke, MD, discussed the role played by the combination of nivolumab plus relatlimab in patients with advanced melanoma.
Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.
A thorough review of promising therapies currently under investigation for the treatment of myelofibrosis.
An expert oncologist overviews quality-of-life data and considerations in treatment sequencing in myelofibrosis.
Mitchell Smith, MD, PhD, discusses the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma.
Matthew Ingham, MD, highlights a recent clinical study in the sarcoma space and discusses what else is being evaluated for this patient population.
The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.
Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.
David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.
Jason Porter, MD, and fellow panelists discuss how expression of NSCLC biomarkers and biomarker testing rates may vary by patients’ clinical characteristics, including tumor histology, stage, race, and sex.
Expert panelists are introduced and review common biomarkers in non-small cell lung cancer (NSCLC), followed by a focused discussion on EGFR mutations.
Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Andrew Kuykendall, MD, discusses some of the recent changes there have been for patients with myeloproliferative neoplasms.
Hussein Tawbi, MD, PhD closes the discussion by outlining current unmet needs in the unresectable metastatic melanoma treatment landscape.
Discussion centered around planning for, managing, and overcoming adverse effects in the first-line systemic therapy setting for melanoma.
Dr Moshe Ornstein provides an overview of renal cell carcinoma (RCC) and treatment considerations for patient who have progressed with advanced RCC.
Yann-Alexandre Vano, MD, discusses the main findings from the phase 2 BIONIKK trial that were presented at the 2023 Genitourinary Cancers Symposium.
Guru P. Sonpavde, MD, discusses The Cancer Genome Atlas and key takeaways for community oncologists.
Yago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.
Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.
